Nathaniel Brandon Lipkus

Nathaniel is an intellectual property litigator and strategist, with an emphasis on patent, commercial IP and life sciences regulatory issues. He is also a registered Canadian patent and trademark agent.

Nathaniel has also advocated on behalf of life sciences clients before numerous regulatory agencies in Canada and the United States on intellectual property, regulatory approval, pricing and reimbursement, and antitrust matters. This advocacy involves managing IP issues, removing barriers to health product approval, and law reform efforts.

In addition to his role as advocate, a significant part of Nathaniel’s practice is assisting emerging and high-growth companies with business-critical intellectual property issues, including IP in large acquisitions, strategic IP licensing, IP risk management, and IP structuring in ongoing operations. This work enables Nathaniel to engage with a high throughput of clients and IP issues at the cutting edge in a variety of technological fields.

Nathaniel also has a depth of experience advising on international trade-related intellectual property matters, having served as Chair of the Intellectual Property Institute of Canada’s IP Trade Policy Committee during Canada’s negotiation of the Canada-European Union Comprehensive Economic and Trade Agreement and Trans-Pacific Partnership.

Authentic Brands Group in its acquisition of a majority stake in the IP of October’s Very Own

Teva Canada in the Federal Court’s strike of judicial review by Novo Nordisk Canada Inc.